We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Improved Detection of Polyomavirus in Merkel Cell Carcinoma

By LabMedica International staff writers
Posted on 20 Nov 2012
An improved detection system suggests that all Merkel cell carcinomas (MCC), a rare skin cancer, harbor Merkel polyomavirus.

The sensitivity of detection of Merkel polyomavirus (MCPyV) in MCC has been improved, enabling high-confidence discrimination between virus-positive and virus-negative tumors.

A team of scientists collaborating with those at the Dana Farber Institute (Boston, MA, USA) analyzed 75 archival formalin-fixed, paraffin-embedded (FFPE) tissue samples of MCC tumor specimens obtained from 60 patients. More...
They performed immunohistochemistry staining with a newly developed mouse monoclonal antibody specific for MCPyV large T antigen. They also developed several quantitative polymerase chain reaction (qPCR) primers and probe sets to determine the viral copy number per tumor cell. Furthermore, they performed mass spectrometry based genotyping of 112 oncogenes and tumor suppressor genes from DNA extracted from these same tumor samples.

The newly developed monoclonal antibody Ab3 showed markedly increased sensitivity in detecting MCPyV large T antigen in 56 of 58 (97%) MCC tumors tested compared with another monoclonal antibody, known as CM2B4, which detected only 80%. Additionally mutations in the gene tumor protein (TP53) were identified in the two tumors that lacked detectable MCPyV. From 75 tumor specimens, only four tumor specimens contained a validated point mutation in any of the 112 oncogenes and tumor suppressor genes evaluated.

The authors concluded that that the presence of MCPyV in MCC is more common than previously reported and that improved detection methods may reveal that all MCC specimens contain viral DNA. The results of this study support the model that the MCPyV T antigens contribute to the pathogenesis of MCC and when their expression is absent, somatic mutations in TP53 and potentially other genes may be selected during oncogenesis. The study was published on November 1, 2012, in the Journal of Clinical Investigation.

Related Links:

Dana Farber Institute




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.